OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

Results from Phase II/III Clinical Trials Show Improvement in Subset of Patients who Developed an Immune Response to Vaccination TAIPEI, TAIWAN, June 04, 2016 — OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that Phase II/III data evaluating the clinical benefit and immunogenicity of OBI-822/OBI-821 (formerly OPT-822/OPT-821), an investigational active immunotherapy in […]

This article is password protected.

To view the content, please enter your password in the field below